OspA lipoprotein of Borrelia burgdorferi is a mucosal immunogen and adjuvant

Vaccine

Volumn 15, Issue 9, 1997, Pages 988-995

  Erdile, Lorne F ^a   Bruno, Guy ^a  

^a Pasteur Merieux Connaught   (France)

Author keywords

Adjuvant; Lipoprotein; Mucosal

Indexed keywords

IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; IMMUNOLOGICAL ADJUVANT; LIPOPROTEIN; OUTER MEMBRANE PROTEIN;

ANIMAL EXPERIMENT; ANTIBODY RESPONSE; ARTICLE; BORRELIA BURGDORFERI; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; MOUSE; MUCOSA; NONHUMAN; PRIORITY JOURNAL; SALIVA;

EID: 0031171377     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0264-410X(96)00295-2     Document Type: Article

References (35)

1. 1 Staats, H.F., Jackson, R.J., Marinaro, M., Takahashi, I., Kiyono, H. and McGhee, J.R. Mucosal immunity to infection with implications for vaccine development. Curr. Opin. Immunol. 1994, 6, 572-583
2. 2 Douce, G., Turcotte, C. and Cropley, I. et al. Mutants of Escherichia coli heat-labile toxin lacking ADP-ribosyltransferase activity act as nontoxic, mucosal adjuvants. Proc. Natl Acad. Sci. USA 1995, 92, 1644-1648
3. 3 Brandt, M.E., Riley, B.S., Radolf, J.D. and Norgard, M.V. Immunogenic integral membrane proteins of Borrelia burgdorferi are lipoproteins. Infect. Immun. 1990, 58, 983-991
4. 4 Erdile, L.F., Brandt, M.-A. and Warakomski, D.J. et al. Role of attached lipid in immunogenicity of Borrelia burgdorferi OspA. Infect. Immunol. 1993, 61, 81-90
5. 5 Johnson, B.J.B., Sviat, S.L. and Happ, C.M. et al. Incomplete protection of hamsters vaccinated with unlipidated OspA from Borrelia burgdorferi infection is associated with low levels of antibody to an epitope defined by mAb LA-2. Vaccine 1995, 13, 1086-1094
6. 6 Chang, Y.-F., Appel, M.J.G. and Jacobson, R.H. et al. Recombinant OspA protects dogs against infection and disease caused by Borrelia burgdorferi. Infect. Immunol. 1995, 63, 3543-3549
7. 7 Philipp, M.T., Lobet, Y. and Bohm, R.P. Jr et al. Safety and immunogenicity of recombinant outer surface protein A (OspA) vaccine formulations in the rhesus monkey. J. Spirochetal Tick-borne Dis., 1996, 3, 1-13
8. 8 Van Hoecke, C., Comberbach, M. and De Grave, D. et al. Evaluation of the safety, reactogenicity and immunogenicity of three recombinant outer surface protein (OspA) lyme vaccines in healthy adults. Vaccine, 1996, 14, 1620-1626
9. 9 Keller, D., Koster, F.T., Marks, D.H., Hosbach, P., Erdile, L.F. and Mays, J.P. Safety and immunogenicity of a recombinant outer surface protein A Lyme vaccine. J. Am. Med. Assoc. 1994, 271, 1764-1768
10. 10 Schoen, R.T., Meurice, F. and Brunet, C.M. et al. Safety and immunogenicity of an outer surface protein A vaccine in subjects with previous Lyme disease. J. Infect. Dis. 1995, 172, 1324-1329
11. 11 Bessler, W.G., Suhr, B. and Buhring, H.-J. et al. Specific antibodies elicited by antigen covalently linked to a synthetic adjuvant. Immunobiology 1985, 170, 239-244
12. 12 Defoort, J.-P., Nardelli, B., Huang, W., Ho, D.D. and Tam, J.P. Macromolecular assemblage in the design of a synthetic AIDS vaccine. Proc. Natl Acad. Sci. USA 1992, 89, 3879-3883
13. 13 Deres, K., Schild, H., Wiesmüller, K.-H., Jung, G. and Rammensee, H.-G. In vivo priming of virus-specific cytotoxic T lymphocytes with synthetic lipopeptide vaccine. Nature 1989, 342, 561-564
14. 14 Schild, H., Deres, K., Wiesmüller, K.-H., Jung, G. and Rammensee, H.-G. Efficiency of peptides and lipopeptides for in vivo priming of virus-specific cytotoxic T-cells. Eur. J. Immunol. 1991, 21, 2649-2654
15. 15 Nardelli, B., Haser, P.B. and Tam, J.P. Oral administration of an antigenic synthetic lipopeptide (MAP-P3C) evokes salivary antibodies and systemic humoral and cellular responses. Vaccine 1994, 121, 1335-1339
16. 16 Reitermann, A., Metzger, J., Wiesmüller, K.-H., Jung, G. and Bessler, W.G. Lipopeptide derivatives of bacterial lipoprotein constitute potent immune adjuvants combined with or covalently coupled to antigen or hapten. Biol. Chem. Hoppe-Seyler 1989, 370, 343-352
17. 17 Schlecht, S., Wiesmüller, K.-H., Jung, G. and Bessler, W.G. Enhancement of protection against Salmonella infection in mice by a synthetic lipopeptide analogue of bacterial lipoprotein in S. typhimurium vaccines. Zbl. Bakt. 1989, 271, 493-500
18. 18 Ma, Y. and Weis, J.J. Borrelia burgdorferi outer surface lipoproteins OspA and OspB possess B-cell mitogenic and cytokine stimulatory properties. Infect. Immun. 1993, 61, 3843-3853
19. 19 Ma, Y., Seiler, K.P., Tai, K.-F., Yang, L., Woods, M. and Weis, J.J. Outer surface lipoproteins of Borrelia burgdorferi stimulate nitric oxide production by cytokine-inducible pathway. Infect. Immun. 1994, 62, 3663-3671
20. 20 Radolf, J.D., Arndt, L.L. and Akins, D.R. et al. Treponema pallidum and Borrelia burgdorferi lipoproteins and synthetic lipopeptides activate monocytes/macrophages. J. Immunol. 1995, 154, 2866-2877
21. 21 Weis, J.J., Ma, Y. and Erdile, L.F. Biological activities of native and recombinant Borrelia burgdorferi outer surface protein A: dependence on lipid modification. Infect. Immun. 1994, 62, 4632-4636
22. 22 Tai, K.-F., Ma, Y. and Weis, J.J. Normal human B lymphocytes and mononuclear cells respond to the mitogenic and cytokine-stimulatory activities of Borrelia burgdorferi and its lipoprotein OspA. Infect. Immun. 1994, 62, 520-528
23. 23 Hauschildt, S., Hoffmann, P. and Beuscher, H.U. et al. Activation of bone marrow-derived mouse macrophages by bacterial lipopeptide: cytokine production, phagocytosis and la expression. Eur. J. Immunol. 1990, 20, 63-68
24. 24 Bromander, A., Holmgren, J. and Lycke, N. Cholera toxin stimulates IL-1 production and enhances antigen presentation by macrophages in vitro. J. Immun. 1991, 146, 2908-2914
25. 25 McGee, D.W., Elson, C.O. and McGhee, J.R. Enhancing effect of cholera toxin on interleukin-6 secretion by IEC-6 intestinal epithelial cells: mode of action and augmenting effect of inflammatory cytokines. Infect. Immunol. 1993, 61, 4637-4644
26. 26 Lee, C.K., Weltzin, R. and Thomas, W.D. Jr et al. Oral immunization with recombinant Helicobacter pylori urease induces secretory IgA antibodies and protects mice from challenge with Helicobacter felis. J. Infect. Dis. 1995, 172, 161-172
27. 27 Marchetti, M., Arico, B., Burroni, D., Figura, N., Rappuoli, R. and Ghiara, P. Development of a mouse model of Helicobacter pylori infection that mimics human disease. Science 1995, 267, 1655-1658
28. 28 Mega, J., McGhee, J. and Kiyono, H. Cytokine and Ig-producer cells in mucosal effector tissues. J. Immunol. 1992, 148, 2030-2039
29. 29 Dunn, J.J., Lade, B.N. and Barbour, A.G.A.G. Outer surface protein (OspA) from the Lyme disease spirochete, Borrelia burgdorferi: high level expression and purification of a soluble recombinant form of OspA. Protein Expression Purif. 1990, 1, 159-168
30. 30 Bromander, A.K., Ekman, L., Kopf, M., Nedrud, J.G. and Lycke, N.Y. IL-6-deficient mice exhibit normal mucosal IgA responses to local immunizations and Helicobacter felis infection. J. Immunol. 1996, 156, 4290-4297
31. 31 Lycke, N., Tsuji, T. and Holmgren, J. The adjuvant effect of Vibrio cholerae and Escherichia coli heat-labile enterotoxins is linked to their ADP-ribosyltransferase activity. Eur. J. Immunol. 1992, 22, 2277-2281
32. 32 Fuchs, H., Wallach, R., Simon, M.M. and Kramer, M.D. The outer surface protein A of the spirochete Borrelia burgdorferi is a plasmin(ogen) receptor. Proc. Natl Acad. Sci. USA 1994, 91, 12594-12598
33. 33 Takahashi, I., Marinaro, M. and Kiyono, H. et al. Mechanisms for mucosal immunogenicity and adjuvancy of Escherichia coli labile enterotoxin. J. Infect. Dis. 1996, 173, 627-635
34. 34 Jackson, R.J., Fujihashi, K., Xu-Amano, J., Kiyono, H., Elson, C.O. and McGhee, J.R. Optimizing oral vaccines: induction of systemic and mucosal B-cell and antibody responses to tetanus toxoid by use of cholera toxin as an adjuvant. Infect. Immunol. 1993, 61, 4272-4279
35. 35 Rioux, C.R., Bergeron, H., Lin, L., Grothe, S., O'Connor-McCourt, M. and Lau, P.C.K. A fusion plasmid for the synthesis of lipoprotein-antigen chimeras in Escherichia coli. Gene 1992, 16, 13-20